Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?

Ovarian cancer is highly prevalent and the second most deadly gynecological cancer (1). It is estimated that globally in the year 2018 there were 295,414 new cases and 184,799 deaths because of this disease. Epithelial ovarian carcinomas account for 85% to 90% of all malignant ovarian cancers, and more than half of those are the histotype serous carcinoma (2).